Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0

作者：

Prezotti, A. ^{[1
,2
]}

Montalvao, S. ^{[1
]}

Marques, A. ^{[3
]}

Ferreira, C. ^{[4
]}

Oliveira, L. ^{[5
]}

Villaca, P. ^{[6
]}

Ferreira Filho, L. ^{[7
]}

Lorenzato, C. ^{[8
]}

Medina, S. ^{[1
]}

Araujo, F. ^{[9
]}

Ozelo, M. ^{[1
]}

机构：

[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil

[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil

[3] HEMORIO, Hematol, Rio De Janeiro, Brazil

[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil

[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil

[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil

[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil

[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil

[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO286-MON

引用

页码：366 / 366

页数：1

共 50 条

[31] Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII [J].

Betts, JP .

BRITISH MEDICAL JOURNAL, 1998, 316 (7141) :1385-1385

[32] Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy [J].

Peerlinck, K. ;

Hermans, C. .

HAEMOPHILIA, 2006, 12 (06) :579-590

[33] Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA [J].

Miranda, G. G. ;

Rodgers, G. M. .

HAEMOPHILIA, 2009, 15 (01) :383-385

[34] B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study [J].

Kessler, CM ;

Gill, JC ;

White, GC ;

Shapiro, A ;

Arkin, S ;

Roth, DA ;

Meng, X ;

Lusher, JM .

HAEMOPHILIA, 2005, 11 (02) :84-91

[35] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIII ARE IMMUNOLOGICALLY DISTINCT IN IN-VITRO ASSAYS [J].

GILLES, JGG ;

SAINTREMY, JMR .

THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) :1213-1213

[36] Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A [J].

Steele, M. R. ;

Nagel, K. ;

Chan, A. K. C. .

HAEMOPHILIA, 2014, 20 (01) :E100-E101

[37] Accumulation of factor VIII and von Willebrand factor during prophylaxis with a plasma-derived von Willebrand FACTOR/FACTOR VIII concentrate during the WIL-31 study [J].

Kateryna, V. V. ;

Vdovin, V. ;

Timofeeva, M. A. ;

Khayat, C. D. ;

Inati, A. ;

Sidonio, R. F., Jr. .

HAEMOPHILIA, 2024, 30 :139-140

[38] Italian consumption of plasma-derived factor VIII after the SIPPET study [J].

Traversa, Giuseppe ;

Trotta, Francesco .

BLOOD TRANSFUSION, 2017, 15 (03) :283-284

[39] STATUS OF CLINICAL INVESTIGATION OF HUMAN FACTOR-VIII DERIVED FROM RECOMBINANT DNA (RFVIII) [J].

SCHWARTZ, RS ;

ABILDGAARD, C ;

ALEDORT, L ;

ARKIN, S ;

BLOOM, A ;

BRACKMANN, H ;

BRETTLER, D ;

DIETRICH, S ;

EGLI, J ;

FUJIMAKI, M ;

FUKUI, H ;

HILGARTNER, M ;

INWOOD, M ;

KASPER, C ;

KERNOFF, P ;

LEVINE, P ;

LUSHER, J ;

MANNUCCI, P ;

ROSE, E ;

SCHARRER, I .

TRANSFUSION, 1990, 30 (03) :277-277

[40] Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient [J].

Rosenfeld, SB ;

Watkinson, KK ;

Thompson, BH ;

Macfarlane, DE ;

Lentz, SR .

THROMBOSIS AND HAEMOSTASIS, 2002, 87 (05) :925-926

← 1 2 3 4 5 →